Publication | Closed Access

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1

Hepatitis CViral HepatitisImmunologyAntiviral TherapyHepatitisVirology12-Week Interferon-free TherapyAntiviral ResponsePhase 2AChronic Viral InfectionAntiviral DrugIl28b C/c PatientsMedicine